Group 1: Sales Channels and Performance - The company’s smoking cessation drug, Varenicline Tartrate Tablets, utilizes a dual-brand strategy (PariKe and Family Pharmacist) and multiple sales channels, including over 100,000 chain stores and more than 600 hospitals, with online sales primarily through JD, Alibaba, and Meituan [2] - The largest sales volume for the smoking cessation drug currently comes from offline chain channels [2] - Sales in hospital channels have not met company expectations, as most hospitals only have smoking cessation clinics available for one or two half-days a week [3] Group 2: Market Expansion and Effectiveness - The time required to see results from expanding the drug to new cities or regions depends on the pharmacy's execution; well-managed pharmacies may show improvement in 2 to 3 months, while others may take longer [3] - Smokers using Varenicline Tartrate Tablets generally see effects within a few days, but a significant proportion experience relapse due to various physiological and psychological factors [3] Group 3: Competitive Landscape - If Pfizer re-enters the Chinese market with its smoking cessation drug, the company believes it would positively impact the market by increasing consumer awareness and expanding the overall market size [3]

Group 1: Product Efficacy and Side Effects - Varenicline tartrate tablets are recommended by WHO and various clinical guidelines for smoking cessation, with clinically validated efficacy [2] - The incidence of nausea as a side effect is approximately 20%, typically transient within the first 1-2 weeks of use [2][3] Group 2: Insurance and Promotion - Smoking cessation medications are generally not included in the medical insurance directory as per the 2020 interim measures [3] - The company has established a "Quit Smoking with Me" WeChat public account to promote smoking cessation knowledge [3] Group 3: Sales and Market Expansion - The company has expanded its smoking cessation product to over 100,000 retail stores, with over 60,000 maintained by the company's team [3] - Each sales representative currently covers approximately 400 stores, with plans to increase the team to around 200 members, aiming for coverage of 600 stores each [3] - The highest revenue-generating product is the urological medication, Tamsulosin hydrochloride sustained-release capsules, which has maintained double-digit growth for several years [3]

截至发稿，仟源医药市值为27亿元。 每经头条（nbdtoutiao）——重大突破！中国这款新药，中美官方都认定有突破性疗效！世界肺癌大会 沸腾了 （记者 曾健辉） 每经AI快讯，仟源医药（SZ 300254，收盘价：10.97元）9月15日晚间发布公告称，公司第五届第三十 三次董事会会议于2025年9月15日以通讯表决的方式召开。会议审议了《关于公司开展融资租赁业务的 议案》等文件。 2024年1至12月份，仟源医药的营业收入构成为：医药制造占比96.68%，DNA基因保存及孕环境检测服 务占比1.93%，保健食品占比0.79%，其他业务占比0.51%，商业占比0.1%。 ...

证券代码：300254 证券简称：仟源医药 公告编号：2025-063 山西仟源医药集团股份有限公司 第五届董事会第三十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山西仟源医药集团股份有限公司（以下简称"公司"）于 2025 年 9 月 12 日 以邮件方式发出第五届董事会第三十三次会议通知及议案，2025 年 9 月 15 日以 通讯表决的方式召开本次会议。本次会议由董事长黄乐群先生主持，应出席董事 9 名，实际出席董事 9 名。出席会议人员对本次会议的召集、召开方式无异议。 本次会议的召集、召开符合《公司法》、《公司章程》和《董事会议事规则》的有 关规定。 二、董事会会议审议情况 出席本次会议的全体董事对本次会议的议案进行了认真审议，并以投票表决 方式审议通过《关于公司开展融资租赁业务的议案》。 经审议：我们认为公司本次办理融资租赁售后回租业务，能够盘活公司固定 资产，拓宽融资渠道，优化融资结构，为生产经营提供长期资金支持。本次开展 融资租赁售后回租业务，不影响公司相关资产的正常使用，不会对公司的生产经 营产生 ...

一、融资租赁业务概述 为盘活现有资产、拓宽融资渠道、满足日常经营的资金需求，山西仟源医药 集团股份有限公司（以下简称"公司"）将开展融资租赁售后回租业务，公司使 用部分固定资产采用售后回租的方式与向平安点创国际融资租赁有限公司（以下 简称"平安点创"）申请融资额不超过 5,000 万元，期限 2 年半。应平安点创要 求，由控股子公司浙江仟源海力生制药有限公司及公司总裁赵群先生为公司在平 安点创的上述融资租赁业务提供连带保证责任。融资租赁事项的相关租赁利率、 租金及支付方式等具体内容以实际签订的协议为准。 公司已于2025年9月15日召开第五届董事会第三十三次会议，审议通过了《关 于公司开展融资租赁业务的议案》。根据《深圳证券交易所创业板股票上市规则》、 《公司章程》等相关规定，本次审议事项属于公司董事会决策权限，无需提交公 司股东会审议。同时，董事会授权总裁或其指派的相关人员在批准的额度内办理 公司融资租赁业务的一切事宜。 公司与平安点创无关联关系，本次融资租赁售后回租事项不构成关联交易， 亦不构成《上市公司重大资产重组管理办法》中规定的重大资产重组。 证券代码：300254 证券简称：仟源医药 公告编号：2 ...

Group 1 - The core point of the article is that Zhao Qun, a major shareholder and the president of Qianyuan Pharmaceutical, increased his stake in the company, becoming the largest single shareholder [1] - Zhao Qun acquired 2,079,900 shares through centralized bidding from September 11 to 12, 2025, representing 0.84% of the total share capital [1] - After the acquisition, Zhao Qun holds a total of 15,781,792 shares, which is 6.36% of the company [1] Group 2 - Zhao Qun's action was supported by his concerted action partner, Huang Lequn, who holds 5,465,060 shares, accounting for 2.20% of the total shares [1] - Together, Zhao Qun and Huang Lequn own a combined total of 8.56% of the company [1] - Following this change, the company still has no actual controller or controlling shareholder [1]

格隆汇9月12日丨仟源医药(300254.SZ)公布，持股5%以上股东、董事、总裁赵群先生于2025年9月11 日-2025年9月12日通过深圳证券交易所证券交易系统以集中竞价交易方式增持了公司股份，增持完成 后，持有公司股份15,781,792股，占公司总股本的6.36%，成为公司单一第一大股东。同时，赵群先生 的一致行动人黄乐群先生持股5,465,060股，占公司总股本的2.20%，赵群先生及其一致行动人黄乐群先 生合计持股21,246,852股，占公司总股本的8.56%。本次单一第一大股东变更不会导致公司股权分布不 符合上市条件，公司第一大股东仍为赵群先生及其一致行动人黄乐群先生，公司仍无实际控制人和控股 股东，不会导致公司实际控制人及控股股东发生变化。 ...

证券代码：300254 证券简称：仟源医药 公告编号：2025-062 山西仟源医药集团股份有限公司 关于持股5%以上股东增持公司股份的比例触及1%的整数倍 暨公司单一第一大股东变更的公告 公司持股 5%以上股东、董事、总裁赵群先生保证向本公司提供的信息内容 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示：持股5%以上股东、董事、总裁赵群先生于2025年9月11日-2025 年9月12日通过深圳证券交易所证券交易系统以集中竞价交易方式增持了公司股 份，增持完成后，持有公司股份15,781,792股，占公司总股本的6.36%，成为公 司单一第一大股东。同时，赵群先生的一致行动人黄乐群先生持股5,465,060股， 占公司总股本的2.20%，赵群先生及其一致行动人黄乐群先生合计持股21,246,852 股，占公司总股本的8.56%。本次单一第一大股东变更不会导致公司股权分布不 符合上市条件，公司第一大股东仍为赵群先生及其一致行动人黄乐群先生，公司 仍无实际控制人和控股股东，不会导致公司实际控制人及控 ...

Core Viewpoint - On September 7, Suzhou Bank disclosed plans for share buybacks by its directors and senior management, while 20 A-share listed companies announced share reductions by their executives and shareholders [1][2]. Group 1: Share Buybacks - Suzhou Bank's directors, supervisors, and senior management plan to buy back shares worth no less than 4.2 million yuan [2]. Group 2: Share Reductions - Multiple directors and executives from Zhuhai Co. plan to reduce their shareholdings [2]. - Specific shareholders of Yingyang Intelligent, including directors, plan to reduce their stakes [2]. - Nantong Yuxiang intends to reduce its holdings by up to 0.66% in Hongde Co. [2]. - Shareholders of Xiangshan Co. plan to reduce their holdings by no more than 3% [2]. - Five directors and executives of Qianyuan Pharmaceutical plan to reduce their holdings by up to 0.1718% [2]. - Controlling shareholders and executives of Xingshuai Co. plan to reduce their holdings by no more than 2.71% [2]. - Vice President Liu Bin of Rongke Technology plans to reduce his holdings by no more than 63,000 shares [2]. - Shareholder Lei Yan Investment of Green Alliance Technology plans to reduce its holdings by no more than 1.63% [2]. - Controlling shareholders and actual controllers of Runhe Materials plan to reduce their holdings by no more than 3% [2]. - Sunshine Life intends to reduce its holdings in Huakang Clean by no more than 3% [2]. - Shareholder Ruan Jilin of Baida Precision plans to reduce his holdings by no more than 0.99% [2]. - Controlling shareholders and actual controllers of Jusa Long plan to reduce their holdings by no more than 3% [2]. - Controlling shareholder Yulide Group of Youlide plans to reduce its holdings by no more than 2% [2]. - Shareholders of Lutianhua plan to collectively reduce their holdings by no more than 3% [2]. - Dazhi Yintai intends to reduce its holdings in Wushang Group by no more than 22.4971 million shares [2]. - Shareholder Shunfeng Investment of Kejie Intelligent plans to reduce its holdings by no more than 3% [2]. - Shareholders of Shangwei Co. plan to reduce their holdings by no more than 3% [2]. - Jiangshan Co. intends to reduce its holdings by no more than 3% [2]. - Water Planning Investment plans to reduce its holdings in Deepwater Planning by no more than 3% [2]. - Controlling shareholder and actual controller Xie Qian of Zhuoyi Information plans to reduce his holdings by no more than 3% [2].

Group 1 - QianYuan Pharmaceutical announced that several executives plan to reduce their holdings in the company by a total of approximately 290,000 shares, which represents 0.1165% of the total share capital [1] - The company's revenue composition for the year 2024 is as follows: pharmaceutical manufacturing accounts for 96.68%, DNA gene preservation and prenatal environment testing services account for 1.93%, health food accounts for 0.79%, other businesses account for 0.51%, and commercial activities account for 0.1% [1] - As of the report, QianYuan Pharmaceutical has a market capitalization of 2.7 billion yuan [2]